LH

Stock splits

$LH chatter on StockTwits

• 
  Rob Lewis@IN0V84d

  $LH Buy Mizuho raises target price to $355 from $320

  View on StockTwits ↗
• 
  Open Outcrier@OpenOutcrier4d

  $LH (-1.2% pre) Labcorp wins FDA approval for melanoma companion diagnostic https://ooc.bz/l/110571

  View on StockTwits ↗
• 
  Nicholas@JFDIBullish5d

  $LH

  View on StockTwits ↗
• 
  Steven Goldstein@dejachartistBullishAug 5

  $LH rally should continue based on 10 similar patterns identified by @dejachart.

  View on StockTwits ↗
• 
  TalkMarkets@TalkMarketsAug 3

  #Replit’s Next Billion-Dollar Opportunity: From #AI Coding Platform To Entrepreneurship Development Platform Also: $LH $PYPL $TEAM $Z https://talkmarkets.com/article/replits-next-billion-dollar-opportunity-from-ai-coding-platform-to-entrepreneurship-development-platform-1785785420

  View on StockTwits ↗
• 
  Rob Lewis@IN0V8Aug 3

  $LH Buy Opportunity JP Morgan raises target price to $360 from $330

  View on StockTwits ↗
• 
  Estimize@EstimizeJul 30

  $LH reported 4.99 EPS and 3,731 revenue for Q2. http://www.estimize.com/intro/lh?chart=historical&metric_name=eps&utm_content=LH&utm_medium

  View on StockTwits ↗
• 
  MarketBeat Earnings@EarningsInsiderJul 30

  https://www.marketbeat.com/earnings/reports/2026-7-30-laboratory-co-of-america-holdings-stock/ $LH Labcorp Earnings Transcript

  View on StockTwits ↗
• 
  Stocktwits Earnings@StocktwitsEarningsJul 30

  $LH Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $3.66 up 28.42% YoY • Reported revenue of $3.73B up 5.78% YoY • Labcorp Holdings Inc. updated its full-year 2026 guidance, now projecting enterprise revenue growth of 5.4% to 6.3% and an adjusted EPS range of $18.10 to $18.55 at the midpoint.

  View on StockTwits ↗
• 
  Small_time_trader@Small_time_traderJul 23

  $DGX $LH DGX >> LH

  View on StockTwits ↗
• 
  Squeezy@TheRealShortSqueezyBullishJul 21

  🚨 $INBS : Today's FDA Progress Update 🇺🇸 Today's news: Intelligent Bio Solutions announced it has successfully completed precision testing, another important step toward its FDA 510(k) submission and planned U.S. commercial launch. 🧪 Latest Update 🔹 Successfully completed precision testing, adding another key validation study to its FDA 510(k) submission. 🔹 The submission package now includes Precision, Method Comparison, Cut off, and Interference studies. 🔹 More than 1,600 tests were completed across 3 production runs and 3 independent testing sites, demonstrating consistent performance. 🔹 Targeting the U.S. drug screening market, estimated at over $5.8B today and projected to surpass $11.2B by 2034, with its fingerprint-based drug testing technology. 🔹 Results are available in under 10 minutes, with sample collection taking only seconds and no blood, urine, or saliva required. Communicated Disclaimer: https://stockresearchtoday.com/inbs/ Sector Peers:$CODX $FLGT $DGX $LH

  View on StockTwits ↗
• 
  Squeezy@TheRealShortSqueezyBullishJul 15

  🧬 $INBS : Could FDA Approval Unlock the Next Leg Higher? Intelligent Bio Solutions is developing a fingerprint based drug screening system that delivers fast, non invasive testing On June 16, the company kicked off another FDA clinical study, marking another step toward its planned 510(k) submission and potential entry into the U.S. drug testing market Recent Highlights: 🔹 FDA clinical program remains on track 🔹 135-patient U.S. multi site study underway 🔹 Operating in 35+ countries with 480+ active customer accounts 🔹 Q3 revenue increased 46% YoY to $1.06M 🔹 Nine-month revenue reached $3.07M, up 39% YoY 🔹 Gross margin climbed above 50% 🔹 Cash position increased to $6.86M 🔹 Secured its 8th European patent while expanding manufacturing capacity With several FDA milestones ahead, growing commercial traction, and improving financials, INBS looks like one to keep on the watchlist Communicated Disclaimer: https://stockresearchtoday.com/inbs/ Sector Peers : $OSUR $QDEL $DGX $LH

  View on StockTwits ↗
• 
  SuperGreenToday@SuperGreenTodayJun 24

  $LH Share Price: $258.69 Contract Selected: Jan 15, 2027 $260 Calls Buy Zone: $18.59 – $22.96 Target Zone: $29.73 – $36.34 Potential Upside: 51% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

  View on StockTwits ↗
• 
  SuperGreenToday@SuperGreenTodayJun 24

  $LH Share Price: $258.69 Contract Selected: Jan 15, 2027 $260 Calls Buy Zone: $17.25 – $21.32 Target Zone: $29.41 – $35.95 Potential Upside: 61% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

  View on StockTwits ↗
• 
  Adam Brennan@AdamBrennan2Jun 16

  $AMN came up on my Reversed DCF screener as pricing in most FCF decline.. potentially lots of value here.. $LH $GH $BTSG $DVA

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.